NCT05180162 is a Phase 1 clinical trial of 68Ga-FAP-2286 in Liver Fibrosis, sponsored by Thomas Hope.

Who is sponsoring NCT05180162?

NCT05180162 is sponsored by Thomas Hope.

What drugs are being tested in NCT05180162?

Interventions in NCT05180162: 68Ga-FAP-2286, Positron Emission Tomography (PET).

What condition does NCT05180162 study?

NCT05180162 studies Liver Fibrosis, Pulmonary Fibrosis, Myocardial Fibrosis.

Is NCT05180162 still recruiting?

NCT05180162 is currently completed. Last updated 21 March 2025.

Last reviewed 2025-03-21 · How we verify

NCT05180162

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

Completed Phase 1 Last updated 21 March 2025

What this trial tests

Phase 1 trial testing 68Ga-FAP-2286 in Liver Fibrosis in 16 participants. Completed in 28 May 2024.

Timeline

9 December 2021

Primary endpoint
28 May 2024

28 May 2024

Quick facts

Lead sponsor	Thomas Hope
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	16
Start date	9 December 2021
Primary completion	28 May 2024
Estimated completion	28 May 2024
Sites	1 location across United States

Drugs / interventions tested

68Ga-FAP-2286 — full drug profile →
Positron Emission Tomography (PET) — full drug profile →

Conditions studied

Liver Fibrosis — all drugs for Liver Fibrosis →
Pulmonary Fibrosis — all drugs for Pulmonary Fibrosis →
Myocardial Fibrosis — all drugs for Myocardial Fibrosis →

Sponsor

Thomas Hope — full company profile →

Who can join

18 and older, any sex, with Liver Fibrosis or Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis. FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on fibroblasts and has been shown to have higher expression in idiopathic pulmonary fibrosis (IPF), cirrhosis, and cardiac fibrosis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Beyond Small Molecules: Antibodies and Peptides for Fibroblast Activation Protein Targeting Radiopharmaceuticals.
Sun X, Wu Y, Wang X, Gao X, et al · · 2024 · cited 18× · PMID 38543239 · DOI 10.3390/pharmaceutics16030345
Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.
Li Y, Liu Q, Jing X, Wang Y, et al · · 2025 · cited 11× · PMID 40656546 · DOI 10.1002/mco2.70292
Unveiling the Tumor Microenvironment Through Fibroblast Activation Protein Targeting in Diagnostic Nuclear Medicine: A Didactic Review on Biological Rationales and Key Imaging Agents.
Fouillet J, Torchio J, Rubira L, Fersing C. · · 2024 · cited 7× · PMID 39765634 · DOI 10.3390/biology13120967
Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy.
Garate-Soraluze E, Martinez-Zubiaurre I, Rodriguez-Ruiz ME. · · 2026 · PMID 42082274 · DOI 10.1136/jitc-2024-009702

Verify or expand the search:

Other trials of 68Ga-FAP-2286

Trials testing the same drug.

NCT04939610 — A Study of 177Lu-FAP-2286 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other recruiting trials for Liver Fibrosis

Currently open trials in the same condition.

NCT07031089 — City-Hospital Collaboration for Early Detection of Liver Fibrosis in Primary Care: A Secondary Prevention Project in the · recruiting
NCT06940375 — Incidence of Liver Disease-Related Outcomes in People With HIV · recruiting
NCT07271576 — Research on the Protective Effects of Phycocyanin Against Liver Fibrosis and Cirrhosis · NA · recruiting
NCT07069725 — The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Partic · Phase 1 · recruiting
NCT07122700 — Evaluation of Non-Invasive Tests for Metabolic Liver Disease · recruiting

Other Thomas Hope trials

Trials by the same sponsor.

NCT07052760 — Imaging of Solid Tumors Using DLL3 SPECT · EARLY_PHASE1 · not yet recruiting
NCT06961084 — Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer · Phase 2 · recruiting
NCT07054346 — Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 · Phase 1 · recruiting
NCT06474533 — Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm · recruiting
NCT04716725 — 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05180162 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Thomas Hope
Last refreshed: 21 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05180162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing